Skip to main content
. 2023 Mar 15;15(6):1779. doi: 10.3390/cancers15061779

Figure 1.

Figure 1

MAGE-A antigens as cancer therapeutic targets. (A) MAGE-A plays a role as the scaffold for the ubiquitin-protein ligase E3, which forms a complex with the TRIM28 protein. The MAGE-A genes are activated by epigenetic modifications, such as demethylation. MAGE-A binds to TRIM28, enhancing the ubiquitin ligase E3, which binds the tumor suppressor p53 and tags it for degradation by the proteasome, thus resulting in tumorigenesis. (B) Small molecule inhibitors of the MAGE-A interaction with partner protein TRIM28 are being developed to exploit MAGE-A proteins as cancer therapeutic targets.